Lapatinib in breast cancer: Clinical experiences and future perspectives

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Giampaglia, M ^a   Chiuri, V E ^a   Tinelli, A ^a   De Laurentiis, M ^b,c   Silvestris, N ^d   Lorusso, V ^a  

^a VITO FAZZI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Anthracycline; Breast cancer; Chemotherapy; EGFR; HER2; Lapatinib; Taxane; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LAPATINIB; LETROZOLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL ABSORPTION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEADACHE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATOBILIARY DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LIVER FUNCTION; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; PNEUMONIA; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FORECASTING; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 78649729937     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70024-4     Document Type: Article

References (60)

1. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 2007, 117:2051-2058.
2. Harari PM, Allen GW, Bonner JA Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25:4057-4065.
3. Pegram MD, Pauletti G, Slamon DJ HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998, 52:65-77.
4. Leferink AE, Simpson JF, Shawver LK, et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-a bigenic mice. Proc Natl Acad Sci USA 2000, 97:9609-9614.
5. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1:85-94.
6. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64:6652-6659.
7. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
8. Spector NL, Xia W, Bums H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005, 23:2502-2512.
9. Rusnak DW, Affleck K, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001, 61:7196-7203.
10. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23:646-653.
11. Zhou H, Kim YS, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004, 58:344-352.
12. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65:18-25.
13. DeSimone PA, Bence AK, Anderson EB, et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol 2002, 21. [abstract 375].
14. Adams VR, Bence AK, Anderson EB, et al. A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Proc Am Soc Clin Oncol 2002, 21. [abstract 374].
15. Pandite L, Burris HA, Jones S, et al. A safety, tolerability, and pharmaco-kinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol 2004, 22(14s). Abstr. 3179.
16. Versola M, Burris HA, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 2004, 22(14s). Abstr. 3047.
17. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
18. Minami H, Nakagawa K, Kawada K, et al. A phase I study of GW572016 in patients with solid tumors. J Clin Oncol 2004, 22(14s). Abstr. 3048.
19. Storniolo A, Burris H, Pegram M, et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J Clin Oncol 2005, 23(16s). Abstr. 559.
20. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced breast cancer. Clin Cancer Res 2008, 14:4484-4490.
21. Lakhai WS, Beijnen JH, Den Boer SS, et al. Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil(5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. J Clin Oncol 2004, 22(14s). Abstr. 2044.
22. Midgley R, Flaherty KT, Haller DG, et al. Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). J Clin Oncol 2005, 23(16s). Abstr. 3086.
23. Safran H, Iannitti D, Miner T, et al. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. J Clin Oncol 2006, 24(18s). Abstr. 124.
24. Dennie T, Alberti D, Oliver K, et al. A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. J Clin Oncol 2009, 27(15s). Abstr. 2579.
25. Storniolo AM, Magrinat B, Rubin P, et al. A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with or without trastuzumab in patients with metastatic breast cancer: an update. Cancer Res 2009, 69(24s). Abstr. 3097.
26. Esteva FJ, Franco SX, Hagan MK, et al. An evaluation of the safety and efficacy of lapatinib plus trastuzumab plus paclitaxel in first-line HER2+ metastatic breast cancer. Cancer Res 2009, 69(24s). Abstr. 5085.
27. O'Connor RA, Kennedy MJ, McDermott SR, et al. Phase I evaluation of lapatinib (L) and epirubicin (E) in patients (pts) with anthracycline (anth)-naive metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15s). Abstr. 1107.
28. Cianfrocca ME, Kaklamani V, Rosen S, et al. A phase I trial of a pegylated liposomal anthracycline (Doxil(tm)) and lapatinib combination in the treatment of metastatic breast cancer: dose-escalation results of an anthracycline and lapatinib combination trial. Cancer Res 2009, 69(24s). Abstr. 3096.
29. Yardley DA, Whorf RC, Bosserman LD, et al. Safety results of lapatinib combined with nab-paclitaxel in women with first- or second-line HER2-overexpressing metastatic breast cancer (MBC). 2009 ASCO Breast Cancer Symposium: Abstr. 245.
30. Kaklamani V, Uthe R, Khan S, et al. Pilot neoadjuvant trial with combination of lapatinib and nab-paclitaxel in HER2+ breast cancer. Cancer Res 2009, 69(24s). Abstr. 1091.
31. Brain E, Dalenc F, Lokiec F, et al. GEP01: a phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): a FNCLCC Group of early phase trials study. J Clin Oncol 2009, 27(15s). Abstr. 1051.
32. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004, 22(14s). Abstr. 3006.
33. Kaplan EH, Jones CM, Berger MS A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2003, 22. Abstr. 981.
34. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as firstline therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005.
35. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26:1066-1072.
36. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009, 10:581-588.
37. Johnston S, Swanton C, Salazar V, et al. Biomarker profiles in trastuzumab (T) refractory HER2+ inflammatory breast cancer (IBC) that predict for survival benefit from lapatinib (L) monotherapy. Cancer Res 2009, 69(24s). Abstr. 706.
38. Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 2006, 100(1s):S5. [abstract 1].
39. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91:639-643.
40. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
41. Lin NU, Diéras V, Paul D, et al. Multicenter phase II trial of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
42. Guarneri V, Frassoldati A, Bottini A, et al. Safety and activity report of a randomized phase II trial of preoperative anthracycline-based chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: CHERLOB trial. Cancer Res 2009, 69(24s). Abstr. 1093.
43. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
44. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
45. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized studycomparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
46. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
47. Gelmon KA, Parulekar W, Rappold E, et al. COMPLETE: phase III study of taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (NCIC CTG MA.31/EGF108919). 2009 ASCO Breast Cancer Symposium: Abstr. 247.
48. Untch M, Kaufmann M, Hilfrich J, et al. Lapatinib can be safely given concomitantly to EC-Doc as neoadjuvant chemotherapy for breast cancer. First planned safety analysis of the Geparquinto study (CBG44). Cancer Res 2009, 69(24s). Abstr. 1094.
49. Tykerb Evaluation After Chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer accessed April 12, 2010. http://clinicaltrials.gov/ct2/show/NCT00374322.
50. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D accessed April 12, 2010. http://clinicaltrials.gov/ct2/show/NCT00490139.
51. Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study accessed April 12, 2010. http://clinicaltrials.gov/ct2/show/NCT00553358.
52. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer 2010, 102:995-1002.
53. Sherril B, Sherif BN, Amonkar MM, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, HER2+ metastatic breast cancer (MBC). 2009 ASCO Breast Cancer Symposium: Abstr. 212.
54. Leary AF, Drury S, Detre S, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16:1486-1497.
55. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006, 99:295-300.
56. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
57. O'Rourke L, Pegram M, Press M, et al. First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UKN), and treatment-naive (TN) populations from EGF30008. J Clin Oncol 2009, 27(15s). Abstr. 1062.
58. Finn RS, Press M, Dering J, et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. J Clin Oncol 2009, 27(15s). Abstr. 1018.
59. Zembryki D, Gomez H, Koehler M, et al. Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15s). Abstr. 1095.
60. Frassoldati A, Guarneri V, Bottini A, et al. Preplanned first-step analysis of LET-LOB neoadjuvant study: a double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer. J Clin Oncol 2009, 27(15s). Abstr. 570.